Published on 2 Nov 2022 on Zacks via Yahoo Finance
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.58 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 30%. A quarter ago, it was expected that this drug delivery technology company would post a loss of $0.57 per share when it actually produced a loss of $0.52, delivering a surprise of 8.77%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.